Plasma Membrane-Associated Sialidase Confers Cancer Initiation, Promotion and Progression
- 1.4k Downloads
Altered sialylation has been implicated in malignant properties of cancer cells. However, the detailed molecular mechanism remains uncertain. Our studies on mammalian sialidases have facilitated understanding of the molecular bases of aberrant sialylation related to malignancy. Among four types of sialidase so far identified in mammalian cells and tissues, the plasma membrane-associated sialidase NEU3, acting preferentially on gangliosides, has been found to be markedly upregulated in various human carcinomas, and involved in promotion of malignant phenotypes including cell migration, invasiveness and cell survival. NEU3 regulates various signaling pathways critical to cellular homeostasis, and its marked increase in cancer causes dysregulation of the physiological processes resulting in enhancement of tumor initiation, promotion, and progression.
KeywordsSialidase Sialic acid Cancer Ganglioside Cell signaling
- Kawamura S, Sato I, Wada T, Yamaguchi K, Li Y, Li D, Zhao X, Ueno S, Aoki H, Tochigi T, Kuwahara M, Kitamura T, Takahashi K, Moriya S, Miyagi T (2012) Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signaling. Cell Death Differ 19:170–179CrossRefGoogle Scholar